2025.09.12
FIRST IMPLANTATION IN THE FIM CLINICAL T···
This announcement is made by Peijia Medical Limited (the “Company”, together with itssubsidiaries, t···
2025.08.04
Peijia Medical’s Hydrophilic Coating Gui···
On July 30, 2025, Peijia Medical independently developed hydrophilic coating ﻪguidewire —specificall···
2025.07.16
FIRST PATIENT IMPLANT IN THE GLOBAL CLIN···
This announcement is made by Peijia Medical Limited (the “Company”, together with itssubsidiaries, t···
2025.07.09
Peijia Medical Showcased Innovative Port···
From July 2 to 6, 2025, Peijia Medical made a remarkable appearance at Beijing Valves
with a range···
2025.07.02
China’s Independently Developed TEER G···
In July 2025, Dr. Jianfeng Chen, leading the R&D
team at Peijia Medical, collaborated with Pro···
2025.05.24
OCC 2025 One-Year Follow-Up Results from···
From May 29 to June 1, 2025, the 19th Oriental Congress of Cardiology (OCC 2025) grandly commenced a···
2025.05.24
EuroPCR 2025 One-Year Follow-Up Results ···
Highlights: The pivotal clinical trial enrolled 116 symptomatic patients with severe aortic reg···
2025.05.23
EuroPCR 2025 30-Day Follow-Up Results fr···
Highlights: 1. The reported results were derived from a single-center feasibility trial and 7 p···
2025.05.23
EuroPCR 2025 One-Year Follow-Up Results ···
Highlights: The pivotal trial enrolled 130 patients (including 10 roll-in patients), all of who···
2025.04.21
ONE-YEAR FOLLOW-UP RESULTS OF THE REGIST···
On April 18, 2025, at the China Valve (Hangzhou) 2025 conference, Prof. Yan Yunfeng from Prof. Song ···
2025.04.15
REGISTRATION APPLICATION FOR TaurusTrio™···
On April 14, 2025, Peijia Medical announced that the NMPA has formally accepted the registration app···
2025.04.08
HighLife granted US FDA Breakthrough Dev···
We are thrilled to congratulate our incredible partner HighLife Medical on receiving the U···